{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:22:06Z","timestamp":1795029726571,"version":"4.10.2"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Lundbeck, LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The efficacy and safety of eptinezumab for preventive migraine treatment in adults have been demonstrated in multiple, large-scale clinical trials. This non-interventional, retrospective, observational chart review was conducted to examine patient response to eptinezumab 100\u00a0mg or 300\u00a0mg every 12\u00a0weeks for 6\u00a0months in the clinical setting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Eight headache specialists who reported early clinical experience with eptinezumab enrolled the first adults (1\u20136 adults per clinician; age\u2009\u2265\u200918\u00a0years) who met predefined selection criteria (including\u2009\u2265\u200912-month history of migraine,\u2009\u2265\u20094 migraine days\/month prior to eptinezumab initiation, receipt of\u2009\u2265\u20092 consecutive eptinezumab doses, and\u2009\u2265\u200912-week follow-up period), and provided detailed patient, disease, treatment, and outcome information via SurveyMonkey and standardized case-report forms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Charts from 31 adults (median age, 49\u00a0years) with migraine (93.6% chronic) who received eptinezumab for the preventive treatment of migraine were reviewed. Most patients (26\/31 [83.9%]) were initiated at 100\u00a0mg. Eptinezumab reduced mean headache frequency (24.3 monthly headache days [MHDs] at baseline; 17.1 MHDs at Month 6); mean migraine frequency (17.3 monthly migraine days [MMDs] at baseline; 9.1 MMDs at Month 6); attack severity (17\/31 [54.8%] patients); acute headache medication use (12.5 acute medication days at baseline; 7.4 at Month 6); and patient-reported disability (11\/22 [50.0%] severe at baseline; 7\/19 [36.8%] at Month 6). More than three-quarters of patients (24\/31 [77.4%]) perceived improved disability\/function and most (30\/31 [96.8%]) perceived eptinezumab to be well tolerated after 6\u00a0months. Most of the headache specialists reported that eptinezumab was well tolerated by patients (30\/31 [96.8%]) and that the intravenous infusion experience was not challenging.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Patients with migraine who received 6\u00a0months of preventive treatment with eptinezumab experienced reductions in migraine and headache frequency, disability, and acute medication use during the course of treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-023-03204-8","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T17:27:27Z","timestamp":1682011647000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Early clinical experience with eptinezumab: results of a retrospective observational study of patient response in the United States"],"prefix":"10.1186","volume":"23","author":[{"given":"Amaal J.","family":"Starling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Kymes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Asher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Soni-Brahmbhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghana","family":"Karnik-Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"3204_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies \u2014 successful translation from bench to clinic. Nat Rev Neurol. 2018;14:338\u201350. https:\/\/doi.org\/10.1038\/s41582-018-0003-1.","journal-title":"Nat Rev Neurol"},{"key":"3204_CR2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrneurol.2010.127","volume":"6","author":"TW Ho","year":"2010","unstructured":"Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010;6:573\u201382. https:\/\/doi.org\/10.1038\/nrneurol.2010.127.","journal-title":"Nat Rev Neurol"},{"key":"3204_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/15360288.2019.1690616","volume":"34","author":"B Henson","year":"2020","unstructured":"Henson B, Hollingsworth H, Nevois E, Herndon C. Calcitonin gene-related peptide (CGRP) antagonists and their use in migraines. J Pain Palliat Care Pharmacother. 2020;34:22\u201331. https:\/\/doi.org\/10.1080\/15360288.2019.1690616.","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"3204_CR4","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1177\/1060028020903417","volume":"54","author":"K Arca","year":"2020","unstructured":"Arca K, Reynolds J, Sands KA, Shiue HJ. Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class. Ann Pharmacother. 2020;54:795\u2013803.","journal-title":"Ann Pharmacother"},{"key":"3204_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1124\/jpet.119.264671","volume":"374","author":"LF Garcia-Martinez","year":"2020","unstructured":"Garcia-Martinez LF, Raport CJ, Ojala EW, et al. Pharmacologic characterization of ALD403, a potent neutralizing humanized monoclonal antibody against the calcitonin gene-related peptide. J Pharmacol Exp Ther. 2020;374:93\u2013103. https:\/\/doi.org\/10.1124\/jpet.119.264671.","journal-title":"J Pharmacol Exp Ther"},{"key":"3204_CR6","unstructured":"Lundbeck Canada Inc. (2021) Product Monograph Including Patient Medication Information: Vyepti (Eptinezumab for injection). https:\/\/www.lundbeck.com\/content\/dam\/lundbeck-com\/americas\/canada\/products\/files\/vyepti_product_monograph_english.pdf."},{"key":"3204_CR7","unstructured":"Vyepti [package insert] (2022). Bothell, WA, Lundbeck Seattle BioPharmaceuticals, Inc. https:\/\/www.lundbeck.com\/content\/dam\/lundbeck-com\/americas\/united-states\/products\/neurology\/vyepti_pi_us_en.pdf."},{"key":"3204_CR8","unstructured":"Lundbeck A\/S Valby D (2021) Vyepti [EMA Authorization]. Valby, Denmark. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vyepti."},{"key":"3204_CR9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40:241\u201354. https:\/\/doi.org\/10.1177\/0333102420905132.","journal-title":"Cephalalgia"},{"key":"3204_CR10","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/j.clinthera.2020.11.007","volume":"42","author":"TR Smith","year":"2020","unstructured":"Smith TR, Janelidze M, Chakhava G, et al. Eptinezumab for the prevention of episodic migraine: sustained effect through 1 year of treatment in the PROMISE-1 study. Clin Ther. 2020;42:2254-2265.e3. https:\/\/doi.org\/10.1016\/j.clinthera.2020.11.007.","journal-title":"Clin Ther"},{"key":"3204_CR11","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020;94:e1365\u201377. https:\/\/doi.org\/10.1212\/WNL.0000000000009169.","journal-title":"Neurology"},{"key":"3204_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-020-01186-3","volume":"21","author":"S Silberstein","year":"2020","unstructured":"Silberstein S, Diamond M, Hindiyeh NA, et al. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy\u20132) study. J Headache Pain. 2020;21:1\u201312. https:\/\/doi.org\/10.1186\/s10194-020-01186-3.","journal-title":"J Headache Pain"},{"key":"3204_CR13","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12883-021-02123-w","volume":"21","author":"D Kudrow","year":"2021","unstructured":"Kudrow D, Cady RK, Allan B, et al. Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. BMC Neurol. 2021;21:126. https:\/\/doi.org\/10.1186\/s12883-021-02123-w.","journal-title":"BMC Neurol"},{"key":"3204_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-021-01227-5","volume":"22","author":"TR Smith","year":"2021","unstructured":"Smith TR, Spierings ELH, Cady R, et al. Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials. J Headache Pain. 2021;22:1\u201311. https:\/\/doi.org\/10.1186\/s10194-021-01227-5.","journal-title":"J Headache Pain"},{"key":"3204_CR15","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1212\/WNL.56.SUPPL_1.S20","volume":"56","author":"WF Stewart","year":"2001","unstructured":"Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) questionnaire to assess headache-related disability. Neurology. 2001;56:S20\u20138. https:\/\/doi.org\/10.1212\/WNL.56.SUPPL_1.S20.","journal-title":"Neurology"},{"key":"3204_CR16","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/A:1026119331193","volume":"12","author":"M Kosinski","year":"2003","unstructured":"Kosinski M, Bayliss MS, Bjorner JB, et al. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res. 2003;12:963\u201374. https:\/\/doi.org\/10.1023\/A:1026119331193.","journal-title":"Qual Life Res"},{"issue":"10","key":"3204_CR17","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1177\/03331024221089567","volume":"42","author":"P McAllister","year":"2022","unstructured":"McAllister P, Kudrow D, Cady R, et al. Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine. Cephalalgia. 2022;42(10):1005\u201312. https:\/\/doi.org\/10.1177\/03331024221089567.","journal-title":"Cephalalgia"},{"key":"3204_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s10194-019-0979-y","volume":"20","author":"V Favoni","year":"2019","unstructured":"Favoni V, Giani L, Al-Hassany L, et al. CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? J Headache Pain. 2019;20:27. https:\/\/doi.org\/10.1186\/s10194-019-0979-y.","journal-title":"J Headache Pain"},{"key":"3204_CR19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/head.14036","volume":"61","author":"H-C Diener","year":"2021","unstructured":"Diener H-C, Marmura MJ, Tepper SJ, et al. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: subgroup analysis of PROMISE-2. Headache. 2021;61:125\u201336. https:\/\/doi.org\/10.1111\/head.14036.","journal-title":"Headache"},{"key":"3204_CR20","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1111\/head.14206","volume":"61","author":"MJ Marmura","year":"2021","unstructured":"Marmura MJ, Diener HC, Cowan RP, et al. Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache. Headache. 2021;61:1421\u201331. https:\/\/doi.org\/10.1111\/head.14206.","journal-title":"Headache"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03204-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-023-03204-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03204-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T17:30:10Z","timestamp":1682011810000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-023-03204-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3204"],"URL":"https:\/\/doi.org\/10.1186\/s12883-023-03204-8","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"assertion":[{"value":"12 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with Good Clinical Practice guidelines, the principles of the Declaration of Helsinki, and all applicable regulatory requirements. Institutional review board approval was obtained from Advarra, Inc, for this protocol on 22 November 2021 (Advarra protocol number: 00059159). Patients provided written informed consent prior to initiation of any study procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AS has received consulting fees from Allergan\/AbbVie, Amgen, Axsome Therapeutics, Eli Lilly, Everyday Health, Impel, Lundbeck, Med-IQ, Medscape, Neurolief, Novartis, Satsuma, Teva, and Theranica.DA and SS-B are employees of Lundbeck LLC.SK and MK-H were employees of Lundbeck LLC when this study was performed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"158"}}